Association for the
Advancement of
Blood & Biotherapies

Hemovigilance Committee

CHAIR: Dr. Opal Reddy, CABP ,MD

PURPOSE: The purpose of the AABB Hemovigilance Committee is to provide strategic and tactical guidance to the AABB and its various hemovigilance programs and activities. Work groups from this committee will focus on educational, data analytics, and advocacy issues serving as resources in the promotion of hemovigilance education, best practices, and donor/patient hemotherapy safety.

CHARGES: 1. Foster the development of demonstration projects with willing and appropriate institutions to demonstrate the value of participation in hemovigilance programs derived from various sources including but not limited to the CDC's NHSN's Hemovigilance Module and to generate publishable data in this regard (To be handled through the Hemovigilance Committee work groups and Donor Hemovigilance Working Group).

2. Promote the adoption of the Donor Hemovigilance system's standardized donor reaction definitions into routine use by blood collectors and into BECS software used by blood collectors (To be handled through Donor Hemovigilance Working Group).

3. Encourage evaluation, dissemination, and use of the accumulated hemovigilance data, thereby promoting the adoption of the hemovigilance monitoring systems for their positive impact on patient/donor safety (To be handled through Hemovigilance Committee work groups).

4. Assure availability of hemovigilance education through the activities of the work groups, including development of tools and resources as needed. Develop and maintain a "Curated Case Archive" to support educational efforts of the committee. Develop data collection tools, forms, and offerings to collect critical supplementary transfusion adverse event related information, not regularly collected by hemovigilance systems, to further enhance hemovigilance activities (To be handled through Hemovigilance Committee work groups).

5. Promote use of common definitions and reporting formats for adverse reactions and incidents/occurrences/events among all interested federal and state agencies (HHS, CDC, AHRQ, FDA, etc.).

6. Promote the development and implementation of systems that allow electronic reporting from EMRs, LISs and BECSs into the recipient and donor systems.

7. Maintain communications with appropriate federal agencies regarding the recipient and donor systems.

8. Encourage regular meetings of CDC Stakeholders and Subject Matter Expert groups to foster user and expert input into the development process and evolution of the CDC NHSN's Hemovigilance Module.

9. Maintain knowledge of and appropriate relationships with hemovigilance systems and organizations worldwide.

10. Explore potential donor/transfusion recipient hemovigilance pertinent issues in pandemic settings (e.g., transfusion reaction associated passive antibody interactions in donor/recipient pairs).

Current Personnel as of January 08, 2025

Name	Roles
Chair	
Dr. Opal Reddy, CABP ,MD	
CHIEF_MEDICAL_OFFICER	
Claudia Cohn, MD, PHD	
Junior Committee Member	

Name	Roles
Mrs. Gina Buscema, BS,MT(ASCP)BB	
Kristina Prus	

Liaison

Wen Lu	TMSCC Liaison
Samantha Ngamsuntikul, MD	Donor Hemovig. WG Liaison
Hamilton Tsang	IS Committee Liaison

Member

Paula Saa, PHD	
Bentley Rodrigue	
Julia Maxwell	
Dr. Sean Stowell	
Mrs. Kimberly S. Charity BS, MT(ASCP), CQA (A	
Dr. Rita Feghali	
Kristen Whitten	
Maryam Asif	
Dr. Angela Treml	
Brian Adkins, MD	
Laura Stephens	
Bhishma Patel	
Aditi Khandelwal, MD,MSC	
Mrs. Melissa A. Cumming	
Shaughn Nalezinski, MLS(ASCP)SBB,MS,MT(AMT)	
Tayler Van Den Akker	
Adriana Knopfelmacher	
Alexandra Budhai, MD	

Representative

James J. Berger	HHS Rep.
Barbee Whitaker, PHD	FDA Rep.
Mary Townsend, MD	ISBT Rep.
Dr Samantha Mack	ABC Rep.
Courtney Lawrence	ARC Rep.
Isabel Griffin, MPH,PHD	CDC Rep.
Dr. Wendy M. Paul, MD	FDA (OBRR) Rep.
DR James Long	ASBP/DHA/U.S. Military

Staff Liaison

Srijana Rajbhandary	

Time Commitment: To learn about the time commitments for this committee, please contact the staff liaison listed in the roster above.